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Background: LAG-3 is a potent negative regulator of the immune response but its impact in HIV infection in
poorly understood. Unlike exhaustion markers such as PD-1, Tim-3, 2B4 and CD160, LAG-3 is poorly expressed on
bulk and antigen-specific T cells during chronic HIV infection and its expression on innate lymphocyte subsets is
not well understood. The aim of this study was to assess LAG-3 expression and association with cellular dysfunction
on T cells, NK cells and iNKT cells among a cohort of healthy and HIV-infected female sex workers in Nairobi, Kenya.
Results: Ex vivo LAG-3 expression was measured by multiparametric flow cytometry, and plasma cytokine/chemokine
concentrations measured by bead array. Although LAG-3 expression on bulk T cells was significantly increased among
HIV-infected women, the proportion of cells expressing the marker was extremely low. In contrast, LAG-3 was more
highly expressed on NK and iNKT cells and was not reduced among women treated with ART. To assess the functional
impact of LAG-3 on iNKT cells, iNKT cytokine production was measured in response to lipid (αGalCer) and PMA/Io
stimulation by both flow cytometry and cytokine bead array. iNKT cytokine production is profoundly altered by
both HIV infection and treatment, and LAG-3, but not PD-1, expression is associated with a reduction in iNKT IFNγ
production.
Conclusions: LAG-3 does not appear to mediate T cell exhaustion in this African population, but is instead
expressed on innate lymphocyte subsets including iNKT cells. HIV infection alters iNKT cytokine production patterns
and LAG-3 expression is uniquely associated with iNKT dysfunction. The continued expression of LAG-3 during
treatment suggests it may contribute to the lack of innate immune reconstitution commonly observed during ART.
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During chronic HIV infection, persistent antigen expos-
ure, microbial translocation and increasing immune acti-
vation lead to the phenomenon of immune exhaustion,
where lymphocyte subsets (most commonly CD8+ T
cells) exhibit a progressive loss of cytotoxicity, cytokine
production and proliferation (reviewed in [1]). The
phenotype of immune exhaustion is often mediated by
the increased and simultaneous expression of inhibitory
surface proteins such as PD-1, Tim-3, LAG-3, CD160* Correspondence: keith.fowke@med.umanitoba.ca
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unless otherwise stated.and 2B4/CD244 on CD4+ and CD8+ T cells. Initiation of
combination antiretroviral therapy (cART) often returns
inhibitory receptor levels to baseline [2,3], and blockade of
these pathways during infection is being considered as a
component of viral eradication strategies [4].
In contrast to highly studied markers such as PD-1
and Tim-3, less is known about the expression and role
of LAG-3 in immune exhaustion during chronic HIV in-
fection. The LAG-3 protein bears structural similarities
to CD4 and binds the same ligand, MHC class II, but
with much greater affinity [5-7]. LAG-3 cross-linking in-
hibits Ca2+ fluxes, T cell proliferation and IFNγ, TNFα
and IL-2 (but not Th2 cytokine) production following
TCR re-stimulation [8,9]. In healthy individuals, its ex vivohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Juno et al. Retrovirology  (2015) 12:17 Page 2 of 17expression is negligible, but it is known to be expressed on
activated T and NK cells [5,10], Tregs [11,12], iNKT cells
[13] and some pDC populations [14]. Microarray studies
of gene expression during multiple stages of HIV/SIV in-
fection indicate modulation of LAG-3 expression [15,16];
LAG-3 transcript levels positively correlate with viral load
set point and are significantly higher among rapid progres-
sors compared to viremic non-progressors [17]. In vitro,
HIV-pulsed DCs can induce the expression of a number
of exhaustion markers, including LAG-3, on T cells [18].
Despite these observations, evidence of LAG-3 in-
volvement in lymphocyte dysfunction during chronic
infection remains elusive. With the exception of one re-
port [19], early studies suggested that LAG-3 is not up-
regulated on bulk T cells during HIV infection [20].
Recent characterization of HIV-specific T cells found
that the major populations of exhausted HIV-specific
CD8+ and CD4+ T cells lack LAG-3 expression [21,22].
Although a recent study reported on a population of
LAG-3+ HIV-specific CD8+ T cells associated with low
viral loads, the authors were unable to detect LAG-3
expression on HIV-specific T cells prior to a 30 hour
stimulation in vitro [23].
Importantly, LAG-3 expression on non-T lymphocyte
subsets during chronic HIV infection has not been
assessed. In HIV infection, NK cells exhibit multiple
functional defects [24,25] that persist during cART [26],
as well as expansion of a dysfunctional CD56−CD16+
subset that expresses high levels of inhibitory receptors
[27]. The invariant NKT (iNKT) population is also af-
fected by HIV infection. iNKTs are innate lymphocytes
and a small subset of CD1d-restricted CD3+ lymphocytes
that respond to lipid antigen stimulation with robust cyto-
kine production and proliferation, creating a potent link
between the innate and adaptive arms of the immune sys-
tem. CD4+ iNKTs are depleted during chronic HIV infec-
tion [28,29] and exhibit variable reconstitution during
ART [28,30,31]. The bulk iNKT population displays also
defects in IFNγ/TNFα secretion and proliferation [30,32-34].
The consequences of iNKT dysfunction or exhaustion
during infection could be considerable due to the unique
role of iNKT cells in linking, and directing, innate and
adaptive immunity. A hallmark of iNKT activation is the
rapid production of a vast array of cytokines and chemo-
kines [35-37]. Other iNKT effector functions include
perforin/granzyme release associated with NKG2D en-
gagement [38-42], and Fas/FasL-mediated cytotoxicity
[36,39]. In addition to direct cytolytic function and cyto-
kine secretion, iNKTs play an important role in the activa-
tion and regulation of other immune cell subsets. iNKT
activation reciprocally modulates DC function [43-45] and
quickly leads to NK cell activation in an IFNγ-dependent
manner, followed by T and B cell activation [46]. Stimula-
tion of iNKT cells in conjunction with soluble T cellantigen enhances both CD4+ and CD8+ antigen-specific
responses [47,48].
Consequently, loss of iNKT function can lead to sig-
nificant defects in adaptive immunity. Data from non-
human primate studies suggests that pre-infection iNKT
frequency correlates with retention of CD4 count follow-
ing SIV challenge, and supernatant from iNKT cultures
is sufficient to inhibit HIV replication in vitro. To date,
the determinants of iNKT dysfunction during HIV infec-
tion are poorly understood. In one study, the exhaustion
marker PD-1, which contributes to loss of T cell func-
tion in HIV infection, was unrelated to iNKT dysfunc-
tion [30], but the role of other inhibitory receptors such
as LAG-3 has not been assessed.
In this context, several gaps in knowledge remain. Al-
though T cell LAG-3 expression is generally low, no
studies to date have included cohorts of African popula-
tions where T cell immune activation is significantly
higher compared to Caucasians [49] and HIV clade A/
D/C infections predominate. We also extended our stud-
ies of LAG-3 expression beyond CD4+ and CD8+ T
cells, given reports of LAG-3 expression on activated
NK and ex vivo iNKT cells and simultaneously assessed
LAG-3 expression on T cell, NK and iNKT subsets
among a population of healthy and HIV-infected Kenyan
commercial sex workers. In a follow-up study, we deter-
mined the functional consequences of the association
between LAG-3 expression and iNKT cytokine production
in chronically infected and ART-treated individuals. This
is the first study to functionally assess LAG-3 on multiple
lymphocyte populations among an African cohort.
Results
LAG-3 Expression screening study
A total of 10 HIV-, 40 HIV+ ART naïve and 40 HIV+
ART experienced women were recruited for the study
(Table 1). The gating strategy for ex vivo samples is shown
in an (Additional file 1). CD3+ and CD3- subsets were
identified by histogram gating. iNKT cells were identi-
fied as CD3 + 6B11+, while conventional T cells were
identified as CD3 + 6B11- and further subgated based
on CD4 and CD8 expression. NK cells were gated as
CD56hiCD16-, CD56dimCD16+ or CD56-CD16+ within
the CD3- population.
We first assessed LAG-3 expression on bulk CD4+
and CD8+ T cell subsets (Figure 1A). Consistent with re-
ports in Caucasian populations [21], LAG-3 expression
was negligible among healthy participants (median 0.14%
CD4 + LAG-3+ and 0.165% CD8 + LAG-3+) (Figure 1B).
LAG-3 expression was significantly affected by HIV infec-
tion on both subsets (p = 0.017 for CD4+, 0.018 for CD8+),
with significant post-test differences between the HIV-N
and HIV+ ART groups (p < 0.05 for CD4+ and CD8+)
(Figure 1B). Despite the significant differences, LAG-3
Table 1 Characteristics of cohort subjects included in the screening study
HIV-N HIV+ ART naïve HIV+ ART experienced p value**
Age, years* 31.5 (28.75, 41) 37 (32.5, 41) 40 (34, 45.25) 0.164
Duration of sex work, years* 9 (5.25, 13.5) 7 (5, 14) 11.5 (5, 19) 0.552
CD4 Count* – 428 (369.3, 632.3) 354 (245, 481) 0.011
Duration of ART, years* – – 2.14 (1.16, 3.64) –
*Data are presented as median (IQR).
**Groups were compared by Kruskal-Wallis test (age, duration of sex work) or Mann–Whitney test (CD4 count).
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ticipant groups (<2% of CD4+ or CD8+ population).
Exhaustion marker expression typically correlates with
disease progression, whether measured by viral load,
CD4 count or immune activation [50,51]. Because viral
load determination is not performed as the standard of
care in Kenya and was not available for these partici-
pants, CD4 count and CD8+ T cell activation (measured
by HLA DR expression) were used as surrogates of diseaseFigure 1 Ex vivo LAG-3 expression on CD4+ and CD8+ T cell subsets.
T cells. (B) LAG-3 expression on both CD4+ and CD8+ T cells among HIV-N, H
CD4 count among HIV+ participants. (D) Correlation and (E) co-expression of
made by Kruskal-Wallis (with Dunn’s post-test), Wilcoxon test and Spearman cprogression. LAG-3 expression did not correlate with
CD4 count on either CD4+ or CD8+ T cells among either
group of HIV+ participants (p > 0.1 for all HIV+, HIV+
ART naïve and HIV+ ART experienced) (Figure 1C).
Similarly, LAG-3 expression did not correlate with CD8+
HLA DR expression on any cell subset among any HIV+
groups (not shown). In addition to CD8+ T cell activation
being an indicator of disease progression, LAG-3 is re-
ported to be expressed primarily on activated T cells.(A) Representative ex vivo surface staining of LAG-3 on CD4+ and CD8+
IV+ and HIV+ ART groups. (C) Correlation between LAG-3 expression and
LAG-3 and CD69 among all HIV+ participants. Statistical comparisons
orrelation. *p < 0.05, ****p < 0.0001.
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expression and acute CD4+ and CD8+ T cell activation
measured by CD69 expression. Notably, LAG-3 and CD69
expression significantly correlated on both CD4+ and
CD8+ T cells (r = 0.560, p = 0.003 for CD4+; r = 0.402,
p = 0.042 for CD8+) (Figure 1D).
To confirm that the negligible T cell LAG-3 expression
in this cohort was specific to LAG-3 and not due to ab-
errant expression of all exhaustion markers, we jointly
assessed LAG-3 and PD-1 expression in a small follow-
up study of 15 HIV-N, 8 HIV+ and 17 HIV+ ART
participants.
Consistent with all published literature [21], PD-1 ex-
pression was robust among all participants and was in-
creased on CD8+ T cells among HIV-infected participants
compared to healthy controls (p = 0.0425) (Additional
file 2A). LAG-3 expression did not correlate with PD-1
expression on CD8+ T cells (Additional file 2B). CD8 +
LAG-3+ T cells, however, expressed significantly more
PD-1 than the bulk CD8+ T cell population (p < 0.0001)
(Additional file 2C), indicating that LAG-3 tends to be
co-expressed with PD-1 on CD8+ T cells during HIV
infection.
We next quantified LAG-3 expression on multiple NK
cell subsets based on CD56 and CD16 expression. As
shown in Figure 2A, NKs were defined as CD56hiCD16−
(immunoregulatory), CD56dimCD16+ (cytotoxic) and CD56−
CD16+ (dysfunctional/anergic) (based on [27,52]). While
Tim-3 is reportedly expressed at high levels, particularly
on CD56dim NKs [53], LAG-3 expression should typically
be restricted to activated NK cells. LAG-3 expression was
detected at low levels on all NK subsets among healthy
individuals (Figure 2A, B). HIV infection altered LAG-3
expression on both the CD56dimCD16+ and CD56hiCD16−
NK subsets, but not CD56−CD16+ NKs (CD56dimCD16+
p = 0.0368, CD56hiCD16− p = 0.0134, CD56−CD16+ p =
0.1474) (Figure 2C). As observed with T cell LAG-3
expression, the significant differences were between the
HIV+ ART experienced women compared to healthy con-
trols (CD56dimCD16+ p = 0.0151, CD56hiCD16− p < 0.05).
The relationship between NK LAG-3 expression and
CD4 count, ART duration and CD4 recovery was virtually
identical to that described for T cell subsets, and exhibited
no significant associations. Intra-participant comparison
of LAG-3 expression across NK subsets revealed signifi-
cantly higher LAG-3 expression on the CD56−CD16+ NK
subset compared to either the CD56dim or CD56hi popula-
tions. The differences remained significant when analysis
was restricted to only HIV- individuals (p = 0.0004, post-
test p < 0.05 for CD56- versus CD56dim, p < 0.01 for
CD56- versus CD56hi) (Figure 2D) or when restricted to
all HIV+ and HIV+ ART participants (p < 0.0001, not
shown). A parametric ANOVA test for linear trend dem-
onstrated a significant decline in LAG-3 expressionacross NK cell subsets with increasing CD56 expression
(CD56- > CD56dim >CD56hi) (p < 0.0001, ANOVA test for
linear trend).
Human iNKT population frequencies are highly vari-
able, ranging from <0.01% of CD3+ T cells to >1% in
published reports [13,54]. We used an antibody specific
to the iNKT TCR (6B11) that is routinely used for iNKT
identification [55-62] and that provides results comparable
to those obtained using CD1d tetramers [63] (Figure 3A).
Unlike murine iNKTs, human iNKT cells can be sub-
grouped as CD4+, CD8α + or double negative (DN) [13].
Some samples contained too few iNKT events for further
analysis, thereby reducing sample sizes for this analysis to
8 HIV-N, 34 HV+, and 34 HIV+ ART participants. Similar
to the depletion of conventional CD4+ T cells during
chronic HIV infection, CD4+ iNKTs are easily infected
and depleted [28]. Consistent with previous reports, the
proportion of CD4+ iNKT cells in this cohort was re-
duced in the HIV+ ART naïve group (p = 0.0012, post-
test p < 0.01 for healthy vs. HIV+). Interestingly, CD4+
iNKT proportion remained low among HIV+ ART expe-
rienced participants (p < 0.001 for healthy vs. HIV+ ART
experienced) (Figure 3B), suggesting no reconstitution of
the CD4+ iNKT compartment in this population during
ART. The proportionate decrease in CD4+ iNKT cells
was associated with an inflated proportion of CD8+
iNKT cells (p = 0.0005, post-test p < 0.01 for healthy vs.
HIV+, p < 0.001 for healthy vs. HIV+ ART experienced),
while the frequency of DN iNKTs remained similar
across groups (Figure 3B).
LAG-3 expression was detected at low levels on iNKTs
among healthy women, and was significantly elevated
during chronic HIV infection among ART experienced
participants (Figure 3C, D) (p = 0.0274, post-test p < 0.05
for HIV- versus HIV+ ART). LAG-3 expression on the
bulk iNKT subset did not correlate with CD4 count
among HIV+ participants, whether grouped together or
stratified by ART use (Figure 3F) (p > 0.1 for all). iNKT
CD4+/CD8+/double negative subset analysis of partici-
pants with sufficient events in each gate demonstrated
that LAG-3 expression was significantly increased only
on the CD4+ iNKT subset among HIV+ ART experienced
individuals (p = 0.029, post-test p < 0.05 HIV- versus HIV+
ART) (Figure 3E). Among all HIV+ participants, iNKT
LAG-3 expression did significantly correlate with iNKT
activation as measured by CD69 expression (Figure 3G)
(r = 0.4507, p = 0.0353).
Given that LAG-3 expression was largely unrelated to
HIV disease progression, we assessed whether LAG-3
expression on any lymphocyte subset was related to
plasma concentrations of IFNα2, IFNγ, IL-4, IL-6, IL-10,
MIP-1β, sCD40L and TNFα quantified by cytokine bead
array. Among participants with detectible analyte levels,
iNKT LAG-3 expression exhibited a weak negative
Figure 2 Ex vivo LAG-3 expression on NK cell subsets. (A) Representative ex vivo surface staining of NK cell subpopulations and (B) LAG-3
expression on CD56dimCD16+ NK cells. (C) LAG-3 expression on the CD56dimCD16+ and CD56hiCD16- NK subsets among healthy and HIV-infected
groups. (D) Paired analysis of LAG-3 expression across NK subsets among HIV-N participants. Statistical comparisons made by Kruskal-Wallis (with Dunn’s
or Mann–Whitney post-test) or Friedman test. *p < 0.05, **p < 0.01.
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infected participants as well as only ART experienced par-
ticipants (r = −0.4291, p = 0.0463 for HIV+/HIV+ ART;
r = −0.6210, p = 0.0438 for HIV+ ART) (Figure 3H).
Assessment of iNKT function
Because LAG-3 was expressed at higher levels on iNKT
cells than T cells or NK cells during HIV infection, we
further explored the relationship between LAG-3 ex-
pression and iNKT cell function in HIV+ participants. A
total of 16 HIV-uninfected, 9 HIV+ ART naïve, and 17
HIV+ ART experienced women were recruited for this
follow-up study. The characteristics of these groups,including age, duration of sex work, CD4 count and dur-
ation of ART are described in Table 2.
Consistent with the screening study, LAG-3 expression
was elevated on iNKT cells during HIV infection (p =
0.004), and was not restored to baseline by ART, as post-
tests revealed significant differences between the HIV-N
and HIV+ ART experienced groups (p < 0.01) (Figure 4A).
In contrast to LAG-3, iNKT PD-1 expression was similar
across groups (Figure 4B). Among all participants, iNKT
LAG-3 expression weakly but inversely correlated with
PD-1 expression (p = 0.023, r = −0.367), a relationship that
persisted as a trend among HIV-infected (HIV+ and HIV+
ART) women (p = 0.098) (Figure 4C). Interestingly, the
Figure 3 Ex vivo LAG-3 expression on iNKT cell populations. (A) Representative ex vivo surface staining of iNKT cells (CD3 + 6B11+) and
sub-gating into CD4+, CD8+ and double negative (DN) subsets. (B) Relative proportion of CD4+ iNKTs within the bulk iNKT population.
(C) Representative staining of LAG-3 on CD3 + 6B11+ iNKT cells. (D) LAG-3 expression on bulk, as well as (E) CD8+, DN and CD4+ iNKT populations
among study groups. (F) Correlation between LAG-3 expression and CD4 count among HIV+ participants. (G) Correlation and (F) co-expression
between CD69 and LAG-3 on iNKT cells among HIV+ participants. (H) Correlation between iNKT LAG-3 expression and plasma IL-10 concentration
among all HIV+ and HIV+ ART participants. Statistical comparisons made by Kruskal-Wallis (with Dunn’s post-test), Wilcoxon test and Spearman
correlation *p < 0.05, **p < 0.01, ***p < 0.001.
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even PD-1 expression itself, on iNKT cells was distinct
from the conventional CD8+ T cell subset. PD-1 expres-
sion on the iNKT subset was significantly higher than on
CD8+ T cells among all participants (p < 0.0001) or when
stratified by HIV status (p < 0.0001 for both HIV-N and
combined HIV+ and HIV+ ART) (Figure 4D). Unlike the
iNKT subset, PD-1 expression was significantly elevated
on CD8+ T cells among HIV+ ART naïve participants
compared to healthy controls (p = 0.010) (Figure 4E) and
no correlation between CD8+ T cell LAG-3 and PD-1expression was observed among HIV+ participants
(p = 0.897) (Figure 4F).
Assessment of iNKT cytokine production
To assess iNKT cytokine production in the Majengo co-
hort, PBMC from HIV-, HIV+ and HIV+ ART experi-
enced participants were stimulated with either the iNKT
lipid antigen αGalCer or the mitogen PMA/Io. IFNγ and
TNFα were measured by intracellular flow cytometry
(Additional file 3). Following stimulation with αGalCer,
HIV status significantly affected IFNγ production by
Table 2 Characteristics of follow-up study participants
Variable* HIV-negative HIV+ ART naïve HIV+ ART experienced p value**
Age, years 40 (34, 44.5) 35 (29, 41) 40 (34.5, 44) 0.522
Duration of sex work 10 (6.5, 12) 9 (5, 14) 11 (8, 20) 0.324
CD4 Count – 475.5 (321, 618) 526.5 (407, 698) 0.297
Duration of ART – – 3 (3, 5.5) –
*Data are presented as median (IQR).
**Groups were compared by Kruskal-Wallis test (age, duration of sex work) or Mann–Whitney test (CD4 count).
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participants producing significantly less IFNγ compared
to healthy controls (post-test p < 0.05). IFNγ production
was only partially restored among the HIV+ ART group,
as the median%IFNγ + cells remained lower than that of
healthy controls (2.43% for HIV+ ART compared to
6.89% for HIV-N and 2.06% for HIV+). TNFα produc-
tion was more similar across subject groups, with only a
trend toward differences in cytokine production based
on HIV status (p = 0.058) (Figure 5B). Similar to the re-
sults observed for IFNγ, the HIV+ ART naïve group ex-
hibited the lowest median cytokine production (1.29%
TNFα + for HIV+ ART naïve compared to 4.74% for
HIV-N and 5.62% for HIV+ ART). When analysing
mono- versus dual-functional iNKT cells, HIV+ ART
naïve participants responded to stimulation with signifi-
cantly fewer double positive TNFα + IFNγ + cells than
healthy controls (p = 0.030, post-test p < 0.05) (Figure 5C),
while the HIV+ ART group exhibited significantly fewer
TNFα-IFNγ + cells in response to lipid stimulation com-
pared to uninfected women (p = 0.017, post-test p < 0.05)
(Figure 5C).
Both bulk IFNγ production and single-positive TNFα-
IFNγ + cell frequencies inversely correlated with iNKT
LAG-3 expression among HIV+ and HIV+ ART women
(p = 0.026, r = −0.522, and p = 0.003, r = −0.662, respect-
ively) (Figure 5D). In contrast, LAG-3 expression did
not correlate with bulk TNFα (Figure 5E), TNFα + IFNγ-
or TNFα + IFNγ + responses (not shown). Ex vivo PD-1
expression did not significantly correlate with either bulk
IFNγ or TNFα cytokine production following stimula-
tion (not shown).
When comparing cytokine expression between CD4+
and CD4- iNKT subsets, HIV-N individuals exhibited
significantly higher IFNγ production by CD4+ iNKTs
(p = 0.006, Figure 5F), a difference which was lost among
HIV+ and HIV+ ART participants (Figure 5F). In contrast,
TNFα production was equivalent between iNKT sub-
sets in both the HIV-N and HIV+/HIV+ ART groups
(Figure 5F). Despite subset-specific differences in IFNγ
production, ex vivo subset-specific LAG-3 expression in-
versely correlated with IFNγ production for both the CD4+
(p = 0.011, r = −0.519) and CD4- (p = 0.005, r = −0.568)
subsets (Figure 5G). The correlation remained significanteven after restricting analysis to HIV+ and HIV+ ART
participants only (p = 0.040, r = −0.663 for CD4+ and p =
0.012, r = −0.735 for CD4-, not shown).
PMA/Io stimulation induced stronger cytokine re-
sponses compared to αGalCer among all participant
groups. Interestingly, IFNγ secretion in response to
PMA/Io stimulation varied significantly among groups
(p = 0.034) (Figure 6A). Although no significant intra-
group differences were detected by Dunn’s post-test,
Mann Whitney comparison of each group demonstrated
significantly lower IFNγ production among both the
HIV+ ART naïve and HIV+ ART groups compared to
healthy controls (p = 0.019 and 0.041, respectively). In
contrast, PMA/Io-induced TNFα secretion was similar
among all groups (p = 0.334) (Figure 6B). The high levels
of cytokine and LAG-3 expression induced by PMA/Io
stimulation allows for a comparison of IFNγ secretion
by LAG-3+ and LAG-3- iNKT cells. Among all partici-
pants with sufficient iNKT cells for sub-gating, LAG-3+
iNKTs were significantly less likely to be IFNγ + than
LAG-3- iNKTs (p = 0.0005, Figure 6C), confirming an
inhibitory activity of LAG-3 on IFNγ production by
iNKT cells.
5 day αGalCer-stimulated cytokine and sLAG-3 production
To investigate the downstream consequences of iNKT
dysfunction during HIV infection of PBMC cytokine/
chemokine production, we collected cell culture super-
natants from 5 day iNKT αGalCer stimulations and
quantified the expression of IFNγ, IL-4, IL-10, IL-13,
IL-17, IP-10, MIP-1α, MIP-1β, and TNFα. IL-17 was
detected above background by <50% of participants in
each group, and was therefore excluded from further
analysis.
The proportion of individuals in each group demon-
strating above-background expression of each analyte
and the background subtracted concentration of each
analyte are reported in Table 3. Significant differences in
analyte concentrations across groups were detected for
IFNγ, IL-13 and IP-10 (p = 0.003, 0.014 and 0.001, re-
spectively, Figure 7A), and there was a trend toward a
reduction in IL-4 concentration (p = 0.095). Post-tests
revealed that inter-group differences were primarily sig-
nificant for the HIV-N versus HIV+ ART experienced
Figure 4 Baseline iNKT LAG-3 and PD-1 expression among healthy HIV-N (n = 14), HIV+ (n = 9) and HIV+ ART (n = 15) women. Comparison of
(A) iNKT LAG-3 expression and (B) iNKT PD-1 expression among HIV-N, HIV+ and HIV+ ART groups in a follow-up study. (C) Correlation between LAG-3
and PD-1 expression all participants and HIV+/HIV+ ART women. (D) Comparison of PD-1 expression on iNKTs compared to conventional CD8+ T cells
among both healthy and HIV-infected women. (E) PD-1 expression on CD8+ T cells among HIV+ ART naïve women (n = 9) compared to healthy
controls (n = 16). (F) Correlation between LAG-3 and PD-1 on CD8+ T cells. Statistical comparisons made by Kruskal-Wallis (with Dunn’s post-test),
Wilcoxon test, Mann–Whitney and Spearman correlation *p < 0.05, **p < 0.01, ****p < 0.0001.





HIV-N All HIV+ G) HIV-N All HIV+
CD4+ iNKT CD4 - iNKT
Figure 5 Functional iNKT cytokine responses to αGalCer stimulation among healthy HIV-N (n = 15), HIV+ (n = 7) and HIV+ ART women
(n = 11). PBMC were stimulated for 10 hours with 100 ng/mL αGalCer, and iNKT production of (A) IFNγ and (B) TNFα were compared between
study groups. (C) Analysis of mono- and dual-functional iNKT αGalCer responses between study groups. Correlation between iNKT LAG-3 expression
and (D) IFNγ or (E) TNFα expression. Comparison of (F) IFNγ and (G) TNFα production by CD4+ and CD4- iNKTs among HIV-N and HIV+/HIV+ ART
participants. (H) Correlation between LAG-3 and IFNγ expression among CD4+ and CD4- iNKT subsets. Statistical comparisons made by Kruskal-Wallis
(with Dunn’s post-test), Wilcoxon test, and Spearman correlation. *p < 0.05, **p < 0.01.
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Given that iNKT activation contributes to NK, B and T
cell activation, these cell types most likely contributed to
the cytokine/chemokine milieu by 5 days post-stimulation.
Ex vivo iNKT frequency significantly correlated with
background-subtracted expression of all analytes except
IL-10 (not shown), suggesting, that cytokine production
was indeed iNKT-driven. Following adjustment for base-
line iNKT frequency, significant differences between
groups in IFNγ (p = 0.009) and IP-10 (p = 0.006) expres-
sion remained, as well as a trend toward differences in
IL-13 (p = 0.055) expression (not shown).In addition to differences in absolute levels of cytokine
production, some studies have described cytokine pro-
duction patterns by expressing the contribution of each
analyte as a proportion of the total cytokine production
by a group [64]. In this analysis, the concentration of
each analyte was summed across all members of a
group, and expressed as a percent of the total cytokines
produced by that group (Figure 7B). In the HIV-N
group, the αGalCer-induced cytokine response is domi-
nated by IP-10, IFNγ and IL-13 expression. In contrast,
the HIV+ ART naïve group demonstrated a relative
expansion in the contribution of IP-10, MIP-1α and
Figure 6 PMA/Io-induced iNKT functional responses. PBMC were stimulated for 6 hours with 25 ng/mL PMA and 500 ng/mL Io, and iNKT
(A) IFNγ production and (B) TNFα production were compared among study groups. (C) Comparison of IFNγ production by LAG-3+ and
LAG-3- iNKTs among all participants. Statistical comparisons made by Kruskal-Wallis (with Mann–Whitney post-test), Wilcoxon test and Spearman
correlation. *p < 0.05, ***p < 0.001.
Table 3 Above-background cytokine responses to αGalCer at 5 days post-stimulation
Analyte HIV-negative (n = 14) HIV+ ART naïve (n = 8) HIV+ ART experienced (n = 14) p value** Post-test differences***
IFNγ N Detectible 13 7 8 0.057
Concentration* 345.9 (76.74, 2115) 34.97 (4.83, 142.7) 2.275, (0.0, 124.8) 0.003 HIV-N vs HIV+ ART
IL-4 N Detectible 7 3 2 0.129
Concentration* 3.06 (0.0, 22.02) 0.0 (0.0, 6.69) 0.0 (0.0, 0.18) 0.095
IL-10 N Detectible 4 2 6 0.618
Concentration* 0.0 (0.0, 5.82) 0.0 (0.0, 4.25) 0.0 (0.0, 13.8) 0.683
IL-13 N Detectible 11 5 6 0.152
Concentration* 199.1 (19.23, 477.0) 8.26 (0.11, 77.2) 0.0 (0.0, 25.45) 0.014 HIV-N vs HIV+ ART
IP-10 N Detectible 11 6 5 0.005
Concentration* 1586 (836.8, 6168) 329.3 (24.5, 5351) 0.0 (0.0, 409.6) 0.001 HIV-N vs HIV+ ART
MIP-1α N Detectible 6 4 4 0.409
Concentration* 0.0 (0.0, 198.4) 37.2 (0.0, 158.5) 0.0 (0.0, 75.6) 0.453
MIP-1β N Detectible 8 4 4 0.368
Concentration* 78.16 (0.0, 370.2) 35.06 (0.0, 165.1) 0.0 (0.0, 104.6) 0.253
TNFα N Detectible 10 7 6 0.084
Concentration* 52.34 (0.0, 317.1) 20.2 (4.74, 115.1) 0.065 (0.0, 140.2) 0.370
*Data are presented as median (IQR) in pg/mL.
**p values obtained from Chi squared tests for N detectible data, Kruskal-Wallis tests for concentration comparisons.
***Dunn’s post-test comparisons with p < 0.05 are indicated for each significant Kruskal-Wallis result Statistical tests with p ≤ 0.1 (trend) are indicated in bold.
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Figure 7 Cytokine/chemokine and sLAG-3 responses 5 days post-αGalCer stimulation among HIV- (n = 15), HIV+ (n = 8) and HIV+ ART
(n = 14) experienced participants. PBMC were stimulated for 5 days with 100 ng/mL αGalCer, and cytokine/chemokine/sLAG-3 concentrations
were quantified in the supernatant. (A) Supernatant concentrations of IFNγ, IL-13 and IP-10 were reduced among HIV-infected participants.
(B) The proportional contribution of each analyte to total cytokine/chemokine expression among participant groups is shown. Aside from IP-10,
HIV-N cytokine production is dominated by IFNγ and IL-13, while HIV+ cytokine production is dominated by TNFα and chemokine expression.
(C) Proportion of subjects exhibiting above-background sLAG-3 production. (D) sLAG-3 concentration among study groups. (E) Correlation of
sLAG-3 concentration IFNγ, IL-13 and TNFα among all participants. Statistical comparisons made by Kruskal-Wallis (with Dunn’s post-test), chi
square test and Spearman correlation *p < 0.05, **p < 0.01, ***p < 0.001.
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relative proportions of IFNγ and IL-13 were somewhat
restored in the ART experienced group, there was a
strong expansion in the contribution of IL-10, MIP-1α,
MIP-1β and TNFα to the total cytokine/chemokine en-
vironment that did not reflect either the HIV-N or HIV+
ART naïve groups.We assessed whether ex vivo iNKT LAG-3 or PD-1
expression was related to cumulative αGalCer-induced
cytokine/chemokine expression, although changes in
LAG-3 and PD-1 expression over the course of cell cul-
ture and the contribution of non-iNKT cells to cytokine
concentrations require that the data be interpreted with
caution. Interestingly, iNKT LAG-3 expression continued
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(r = −0.492, p = 0.004 and r = −0.458, p = 0.014, respect-
ively), and trended toward an inverse correlation with
IL-13 (p = 0.089) among all participants (Additional file 4).
In contrast, PD-1 positively correlated with IFNγ, IL-4 and
IP-10 concentrations among all participants (r = 0.399,
p = 0.024; r = 0.512, p = 0.003; and r = 0.451, p = 0.016,
respectively) (Additional file 4).
sLAG-3 concentration was quantified in the 5 day
αGalCer stimulated cultures to determine whether large
quantities of sLAG-3 were associated with a reduction
in cytokine secretion. sLAG-3 production above back-
ground was detectible in 16/37 samples. Chi square
analysis of the proportion of participants exhibiting
above-background sLAG-3 levels showed significant dif-
ferences between groups (p = 0.020), with HIV+ ART
naïve patients being highly unlikely to produce sLAG-3
in response to stimulation (Figure 7C). sLAG-3 concen-
tration varied significantly across groups (p = 0.017),
with post-tests demonstrating significant differences be-
tween HIV-N and HIV+ ART naïve groups (p < 0.05)
(Figure 7D). Following adjustment for ex vivo iNKT fre-
quency, significant differences in sLAG-3 production
remained (p = 0.026, HIV-N vs HIV+ post-test p < 0.05).
Among all participants, sLAG-3 concentration signifi-
cantly and positively correlated with all analytes except
IL-10 and IL-4 (Additional file 5, Figure 7E). Among
HIV-N participants, sLAG-3 significantly correlated with
only IFNγ and TNFα (Additional file 5).Discussion
The major goals of this study were to assess T cell LAG-3
expression in a population with high immune activation
and to compare LAG-3 expression levels on T cell, NK
and iNKT cell populations during chronic infection and
treatment. To our knowledge, this is the first report of T
cell LAG-3 expression in an African cohort that is known
to have high levels of immune activation. Although T cell
LAG-3 expression was significantly elevated among HIV-
infected participants compared to healthy controls, its ex-
pression remained extremely low among all individuals.
These results are consistent with some reports of CD4 +
LAG-3+ and CD8 + LAG-3+ T cell frequency during
HIV infection [20], but not all [21]. It is interesting that
the participants with the highest levels of LAG-3 expres-
sion were ART experienced, given that exhaustion and
activation marker expression generally declines following
ART initiation, even though immune function is not
fully restored [2,3]. Although the cohort described by
Yamamoto et al. [21] did demonstrate a decline of LAG-3
expression on bulk CD8+ T cells, they noted that LAG-3
expression on central memory cells (the memory subset
with highest LAG-3 expression) did not decline amongART experienced patients, further suggesting that LAG-3
expression is not affected by viral suppression.
Surprisingly, the frequency of LAG-3+ cells in any
lymphocyte subset studied was unrelated to disease
progression (measured by CD4 count or CD8+ HLA DR
expression) or ART duration. This is highly unusual
compared to other exhaustion markers, which generally
correlate well with multiple measures of disease progres-
sion and viremia [50,65,66]. Although LAG-3 expression
correlated with CD69 expression, the two markers were
rarely co-expressed. This likely reflects upregulation of
LAG-3 following acute cellular activation, but with ex-
pression kinetics that are distinct from those of CD69.
The weak correlation between iNKT LAG-3 expression
and plasma IL-10 concentration was the only correlation
observed between lymphocyte LAG-3 expression and
plasma cytokines or chemokines. It is, therefore, difficult
to determine what biological marker drives LAG-3 expres-
sion. It is possible that LAG-3 expression on iNKT cells
directly regulates IL-10 production, but perhaps more
likely that the relationship with IL-10 reflects cross-talk
between iNKT cells and other IL-10-producing lympho-
cyte subsets such as Tregs or neutrophils, both of which
can interact with iNKTs [67,68]. Given that IL-10 can cor-
relate with viral load [69], it is also possible that this rela-
tionship reflects a dependence of LAG-3 expression on
disease progression, although that seems less likely given
the lack of correlation between LAG-3 and CD4 count in
this cohort.
Unlike Tim-3 [70], LAG-3 was not highly expressed
on any NK cell subset. The differences in LAG-3 expres-
sion between NK subsets, however, warrant further inves-
tigation. Although LAG-3 expression was not elevated on
CD56-CD16+ NK cells among HIV+ participants, its ex-
pression was highest on this subset among healthy con-
trols. The expansion of this subset during HIV infection
has been documented [71], and LAG-3 could contribute
to the anergic phenotype observed among these cells.
In contrast to the T cell, and to some extent NK cell,
subsets, LAG-3 was expressed at moderate levels on
iNKT cells, particularly among the HIV-infected partici-
pants. In some patients, up to 40% of the iNKT popula-
tion was LAG-3+, raising the possibility that iNKT cell
function may be regulated by LAG-3 to a greater extent
than other lymphocyte populations. iNKT cells express
surface markers characteristic of both T and NK cells
and respond to lipid antigen presentation by CD1d. Des-
pite the low frequency of the iNKT population in the
periphery (0.01 – 1% of CD3+ lymphocytes in humans),
iNKT activity is now appreciated to play an important
role in immunity to infectious diseases [72]. During
chronic HIV infection, the CD4+ iNKT subset is de-
pleted [28,29], as observed in our present cohort. While
some cohorts report full recovery of both CD4+ and
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no effect of therapy [28,30] similar to the lack of CD4+
iNKT reconstitution seen during this study.
Surprisingly, the increase in LAG-3 expression did not
correspond to increased PD-1 expression, in contrast to
another report by Moll et al. [30]. In both cohorts, iNKT
PD-1 expression was several-fold higher than T cell PD-1
expression, but PD-1 was more readily detected on both
cell subsets in our cohort. Differences in cohort ethnicity
could contribute to the contrasting observations, but it
is also plausible that the use of the EH12.2H7 anti-PD-1
clone coupled to the extremely bright Brilliant Violet
421 fluorochrome enabled more sensitive detection of
PD-1 expression in this study than other clones and
fluorochromes.
To determine the impact of iNKT LAG-3 expression,
we assessed functional iNKT cytokine production cap-
acity in the Majengo cohort. Studies of iNKT function
during HIV infection and treatment in the literature suf-
fer from lack of replication in multiple cohorts, and the
only functional study performed in an African cohort re-
ported only PMA/Io-stimulated cytokine production
from ART-naïve subjects [33]. The decrease in αGalCer-
induced IFNγ expression is similar to other cohorts, but
the lack of functional reconstitution among ART experi-
enced participants in this cohort is concerning [30,34].
Data on iNKT recovery during ART is inconsistent, as
some studies suggest an improvement of iNKT cytokine
production following ART [32,73], while other studies
have failed to find ART-based improvement of iNKT
function [30], or have not differentiated between treated
and untreated subjects [34].
In this study, the ex vivo expression of LAG-3 on the
iNKT subset inversely correlated with IFNγ secretion as
measured by ICS following αGalCer stimulation. The
consistent relationship between LAG-3 expression and
IFNγ secretion for both CD4+ and CD4- iNKTs suggests
a similar consequence of LAG-3 expression on both
subsets, despite differences in IFNγ production between
subsets in healthy individuals. The inhibitory activity of
LAG-3 on iNKT IFNg expression was further confirmed
by the demonstration that LAG-3+ iNKTs are highly un-
likely to produce IFNγ following PMA/Io stimulation.
The association of LAG-3, but not PD-1, with iNKT
dysfunction during HIV infection is broadly consistent
with a previous study of iNKT PD-1 expression [30]. Al-
though PD-1 expression was elevated among HIV-
infected subjects in that cohort, its expression did not
correlate with cytokine production or proliferation, and
blocking of the PD-1/PD-L1 pathway did not improve
proliferation or IFNγ secretion. To date, the contribu-
tion of other exhaustion markers (Tim-3, CD160, 2B4)
to iNKT function during HIV infection has not been de-
fined. The contribution of Tim-3 to iNKT inhibitionduring herpes simplex virus infection was assessed, but
found to be not responsible for the defects in cytokine
secretion [74].
The only surface marker previously demonstrated to
inversely correlate with iNKT cytokine production dur-
ing HIV infection is the costimulatory molecule CD161
[34]. CD161 is expressed by a variable, but generally
high, proportion of iNKT cells [34,75,76]. The regulatory
nature of CD161 on iNKT cells has not been fully clari-
fied, as CD161+ iNKT cells are more likely to produce
IFNγ and TNFα than CD161- cells in healthy individuals
[76,77]. Our study, however, did not assess CD161 ex-
pression and therefore cannot confirm or rule out a con-
tribution of CD161 upregulation to iNKT dysfunction.
To complement the ICS data, we also assessed cyto-
kine/chemokine expression in cell culture supernatant
after 5 days of αGalCer stimulation. In this assay, the
background subtracted supernatant protein levels repre-
sent both iNKT cytokine expression and protein expres-
sion by other cell subsets in response to iNKT activation.
As such, this data represents the downstream, cumulative
impact of lipid stimulation/iNKT activation in a mixed
culture. Give that iNKT activation is known to regulate a
large number of other cell types, and that the functional
impact of LAG-3 expression (which binds MHCII pro-
teins) can only be truly assessed when MHCII-expressing
cells are present, measuring cytokines in a whole PBMC
culture may be more relevant than sorting and isolating
iNKT cells. The correlation between iNKT frequency and
analyte concentration strongly suggests that the measured
analyte levels are iNKT-induced.
Overall, several patterns emerged from analysis of
cytokine/chemokine expression levels and correlations.
Among HIV-N participants, IFNγ and IL-13 were the
major cytokines produced in culture after IP-10. IFN-γ
is a hallmark cytokine produced upon αGalCer stimula-
tion, and IL-13 is produced by activated iNKT cells and
directs monocyte to DC differentiation [78]. The loss of
IL-13 secretion among HIV+ participants likely reflects,
at least partially, the depletion of the CD4+ iNKT subset,
which is reportedly the sole iNKT subset to produce IL-13
[64,79]. In contrast, cytokine production among HIV+ ART
naïve participants was mostly limited to IP-10 and MIP-1α/
β production. The ART experienced group never produced
significantly higher levels of any analyte compared the
ART naïve group, and showed little evidence of iNKT re-
constitution. These data suggest that in addition to a lack
of reconstitution of iNKT function among ART experi-
enced patients, the cytokine production profile is altered
in comparison to both HIV-N and ART-naïve subjects.
The correlations between sLAG-3 production and
cytokine/chemokine concentrations among all study
groups suggest that sLAG-3 may simply be a marker of
iNKT activation. There is no evidence that increasing
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of cytokine production. The lack of production of
sLAG-3 in HIV+ ART naïve, but not ART-treated, par-
ticipants is distinct compared to other cytokine/chemo-
kine responses, which were generally absent in the ART
treated group. The production of sLAG-3 by iNKT cells
following stimulation has not been described in the lit-
erature, and represents a significant gap in knowledge.
The correlation between LAG-3 expression and super-
natant IFNγ at 5 days post-stimulation is consistent with
the ICS results described above. It is important to note,
however, that changes in LAG-3 expression during cul-
ture, and the contribution of other PBMC cell subsets to
cytokine production make a direct link between LAG-3
expression and long-term cytokine production difficult.
The positive correlations between PD-1 expression and
cytokine production also suggest that PD-1 may indicate a
more activated, rather than exhausted, iNKT phenotype.
In conclusion, we have demonstrated both short-term
and long-term defects in iNKT cytokine/chemokine ex-
pression in response to lipid stimulation in a Kenyan co-
hort of HIV+ ART naïve and experienced women.
Although PD-1 expression did not appear to mediate
iNKT dysfunction, the elevated expression of LAG-3 was
associated with an inhibition of IFNγ production, sug-
gesting that LAG-3 at least partially regulates iNKT func-
tion during chronic infection. Coupled with previous
observations from our lab, and others, that LAG-3 is
poorly expressed on T cells during HIV infection, block-
ade of LAG-3 signaling may selectively restore innate im-
mune function and, therefore, improve current treatment
regimens.
Conclusions
Overall, our data suggest that LAG-3 is unlikely to play a
significant role in T cell immune exhaustion in an African
population. Unexpectedly, LAG-3 upregulation during
chronic HIV infection and treatment may be restricted to
the iNKT innate lymphocyte subset. The maintenance of
LAG-3 expression during ART suggests that it may con-
tribute to the innate immune dysregulation observed
among ART subjects, as well as contributing to the loss of
iNKT cytokine production observed during chronic infec-
tion. Future studies that demonstrate the cell-intrinsic
activity of LAG-3 expression will determine whether
blocking LAG-3 activity could improve innate immune re-
sponses initiated by iNKT cells during HIV infection or
treatment.
Methods
Study subjects (n = 90)
This study recruited 10 HIV-uninfected, 40 HIV-infected
antiretroviral naïve and 40 HIV-infected antiretroviral
experienced patients from the Majengo commercial sexworker cohort located in Nairobi, Kenya. In a follow-up
study, an additional 16 HIV-N, 9 HIV+ and 17 HIV+
ART participants were recruited. The Majengo cohort is
an open cohort established in 1984 that recruits both
HIV- and HIV+ commercial sex workers. During a rou-
tine clinic visit, participants provided peripheral blood
samples, and CD4 count was determined for HIV+ par-
ticipants. The study was approved by ethics boards at
both the University of Manitoba and the University of
Nairobi, and all participants provided informed consent.
Flow cytometric analysis
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from whole blood by Ficoll gradient separation.
After isolation, cells were immediately stained for
ex vivo flow cytometric analysis and plasma samples
were collected and frozen for cytokine bead array assay.
The following fluorochrome-conjugated antibodies were
used in various combinations: LAG-3 FITC (clone 17B4,
Enzo Life sciences), iNKT TCR PE (clone 6B11), CD69
PeCy5, CD3 Pacific Blue, CD8 V500, CD56 APC, CD4
Alexa700, CD16 APC-H7, HLA DR APC-H7, CD3
Alexa700, CD3 PeCy5, TNFα PeCy7, IFNγ Alexa700 (all
from BD Biosciences), and PD-1 Brilliant Violet 421
(clone EH12.2H7, Biolegend), Live Dead viability dye
(Invitrogen). Depending on the experiment, 1 – 2×106
cells were stained for surface markers for 30 minutes at
4°C. Cells were resuspended in 1% paraformaldehyde so-
lution and acquired on the BD LSRII flow cytometer. A
minimum of 100,000 lymphocyte events were collected
using BD FACS Diva. Analysis was performed using
FlowJo version 7.5 (Treestar).
For stimulation experiments, cells were either stimu-
lated with 25 ng/mL PMA and 500 ng/mL ionomycin
for 6 hours, or 100 ng/mL of αGalCer for 10 hours.
Golgi stop and golgi plug were added to the cell culture
2 hours post-stimulation to capture cytokine production.
Cells were surface stained above, permeabilized with BD
Cytofix/Cytoperm solution and stained for IFNγ and
TNFα for 30 minutes at 4°C. Because αGalCer stimula-
tion was observed to strongly downregulate the iNKT
TCR, the 6B11 antibody was added at the time of stimu-
lation to identify cells with downregulated TCR, similar
to protocols for CD8+ T cell tetramer staining. Cells
were also stimulated with 100 ng/mL αGalCer for 5 days
and the culture supernatant collected for quantification
of cytokine secretion by bead array.
Plasma cytokine and chemokine concentrations
Concentrations of cytokines and chemokines in plasma
samples were quantified using Milliplex MAP bead array
kits (Millipore) according the manufacturer’s 2 hour
protocol. The Human Cytokine/Chemokine bead panel
included the following analytes (with given limits of
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(0.6 pg/mL), IL-6 (0.4 pg/mL), IL-10 (0.5 pg/mL), MIP-
1β (4.8 pg/mL), sCD40L (9.9 pg/mL) and TNFα (1.6 pg/
mL). Cell culture supernatants from the iNKT αGalCer
stimulations were analysed for expression of the follow-
ing analytes (with corresponding sensitivities): IFNγ
(0.8 pg/mL), IL-4 (4.5 pg/mL), IL-10 (1.1 pg/mL), IL-13
(1.3 pg/mL), IL-17 (0.7 pg/mL), IP-10 (8.6 pg/mL),
IL-12p70 (0.6 pg/mL), MIP-1α (2.9 pg/mL), MIP-1β
(3.0 pg/mL) and TNFα (0.7 pg/mL). Plates quantifying
cytokines in cell culture supernatants used RPMI-1640
media + 10% FBS as the matrix for standard, control and
background wells. Data were acquired on a Bio-Plex 200
(Bio-Rad) and analysed with Bioplex Manager software
(version 5.0, Bio-Rad). Standard curves for each analyte
were generated using 5 parameter logistic regressions.
Samples below the limit of detection were assigned a value
of half of the detection limit.
Soluble LAG-3 ELISA
Quantification of sLAG-3 was performed by in-house
optimized ELISA. 96 well plates were coated with 5 μg/mL
of coating antibody (anti-LAG-3 clone 11E3, Enzo Life sci-
ences) and incubated with 100 μL of sample. A 10-point
standard curve was generated using doubling dilutions of
recombinant human LAG-3-Fc (Enzo Life Sciences) from
8 ng/mL to 15.6 pg/mL diluted in RPMI-1640 + 10% FBS
media. sLAG-3 was detected by the addition of 0.5 μg/mL
of anti-LAG-3-biotin (clone 17B4) and streptavidin HRP.
Super sensitive TMB (Sigma) was used as the colorimetric
substrate and after the addition of a 3% HCl stop solution,
the optical density was measured at 450 nm.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
version 6.0. Two and three group comparisons were per-
formed using the non-parametric Mann–Whitney and
Kruskal-Wallis (with Dunn’s post-test in the event of a sig-
nificant Kruskal-Wallis p value) tests, respectively. Corre-
lations were performed using Spearman’s rho value.
Comparison of intra-patient (matched) data was carried
out by Wilcoxon matched-pairs test (2 groups) or Friedman
test (3 groups). Categorical variables (such as the presence
or absence of an above-background cytokine response)
were compared by chi squared analysis. p values < 0.05
were considered to be statistically significant.
Additional files
Additional file 1: Representative ex vivo staining of PBMC samples
to identify lymphocyte populations. Singlets were identified by FSC-A
versus FSC-H plot. Lymphocytes were gated by FSC-A versus SSC-A. The
CD3- population was subgated into three NK cell subsets based on CD56
and CD16 expression. The CD3+ population was subgated into CD3 +6B11+ iNKT cells and CD3 + 6B11- T cells. Both populations were further
gated by CD4 and CD8 staining.
Additional file 2: (A) PD-1 expression on CD8+ T cells among
HIV-infected participants compared to healthy controls. (B) Correlation
between PD-1 and LAG-3 expression on CD8+ T cells among all
participants. (C) Representative staining of LAG-3 on CD8+ T cells, and
PD-1 expression on CD8 + LAG-3+ T cells. (D) PD-1 expression on CD8 +
LAG-3+ T cells compared to bulk CD8+ T cells. Statistical comparisons
made by Mann–Whitney test, Wilcoxon test and Spearman correlation.
*p < 0.05, **p < 0.01, ****p < 0.0001.
Additional file 3: Representative surface and cytokine staining of
iNKT stimulations. Singlets were identified by FSC-A versus FCS-H
gating, followed by gating on the lymphocyte population. Aberrant
fluorescence signals were excluded by gating on FITC fluorescence over
time. Dead cells were excluded by Live/Dead viability staining. iNKT cells
were gated as CD3 + 6B11+. Intracellular staining of IFNγ and TNFα and
surface staining of LAG-3 and PD-1 is shown for media (negative control),
PMA/ionomycin and αGalCer stimulations.
Additional file 4: Correlations between ex vivo iNKT LAG-3 and
PD-1 expression with 5 day post-αGalCer stimulation cytokine
production among all participants.
Additional file 5: Correlation between background-subtracted
sLAG-3 concentrations at 5 days post αGalCer-stimulation and
supernatant cytokines/chemokines.Competing interests
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